Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients
Postoperative Hemorrhage, Postoperative Anemia, Postoperative Blood Loss
About this trial
This is an interventional treatment trial for Postoperative Hemorrhage focused on measuring Cardiac surgery, Postoperative coagulopathy, Autologous whole blood transfusion, Acute normovolemic hemodilution, Intraoperative autologous transfusion
Eligibility Criteria
Inclusion Criteria: Adult (≥18 yr) Surgical patients at the Mazankowski Alberta Heart Institute High risk for acquired coagulopathy Exclusion Criteria: Left ventricular ejection fraction <20% Impaired renal function Preoperative anemia (hematocrit < 30%) Abnormal coagulation studies or platelet function Presence of hemoglobinopathy Platelet count < 120 10*9/L Non-heparin based CPB anticoagulation Presence of carotid stenosis (≥70%) Presence of bacteremia/endocarditis Age > 85 yr Weight < 55 kg Hepatic failure/dysfunction Pregnancy Chronic lung disease on home O2 Acute respiratory failure Acute coronary syndromes Emergency surgery
Sites / Locations
- University of Alberta
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Autologous Whole Blood Management
Allogenic and Derivative Transfusion
Intraoperative high volume autologous whole blood withdrawal prior to cardiopulmonary bypass (CPB) with re-transfusion following weaning from CPB.
Control arm participants will receive standard care involving transfusion of plasma, platelets, cryoprecipitate, and/or lyophilized concentrates following weaning from CPB.